FDA Guides Industry on New Drug Exclusivity Perks
Published Date: 3/4/2026
Notice
Summary
The FDA just dropped a draft guide to help drug makers understand how to get 3-year exclusivity for new clinical studies on their drugs. This means companies can protect their new research from competition for three years, encouraging innovation. If you’re in the drug business, get your comments in by May 4, 2026, or risk missing out on shaping the final rules!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
3‑year exclusivity blocks certain approvals
Under the cited statutory provisions (Hatch‑Waxman/section 505), a granted 3‑year New Clinical Investigation exclusivity means that 505(b)(2) applications and abbreviated new drug applications (505(j)/ANDAs) may not be approved for the exclusivity‑protected conditions of approval for three years after approval.
Draft guide explains 3‑year exclusivity
The FDA published a draft guidance titled “New Clinical Investigation Exclusivity (3‑Year Exclusivity) for Drug Products: Questions and Answers” to help applicants request 3‑year exclusivity under 21 U.S.C. 355(c)(3)(E)(iii)-(iv) and 355(j)(5)(F)(iii)-(iv). The guidance explains the statutory and regulatory eligibility criteria, how FDA will make eligibility determinations, recommends content/format in a Q&A style, and invites comments by May 4, 2026.
Template provided with no extra paperwork
The draft guidance includes a model template (in the Appendix) that FDA recommends applicants use to request New Clinical Investigation (3‑year) exclusivity. FDA tentatively concludes that providing the template “adds no further information collection requirements and imposes no further burden” beyond existing requirements covered by OMB control number 0910-0001.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-04290 — Proposed Collection; Comment Request
The Pentagon Force Protection Agency wants your thoughts on a new info collection about Pentagon access and visitor management. If you deal with Pentagon entry or visits, this could affect you. They’re asking for comments by May 4, 2026, to make sure the process is clear, useful, and not a hassle—no extra costs expected.
Next: 2026-04292 — Proposed Collection; Comment Request
The Pentagon Force Protection Agency wants your thoughts on updating some forms they use to recruit and check the health and fitness of their team. If you’re involved or interested, you can comment until May 4, 2026. This update aims to make the forms clearer and easier to fill out, with no extra costs expected.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in